Synodos for Schwannomatosis, an international consortium of clinicians and scientists from multiple disciplines, was launched at a full team meeting in Toronto, Canada on May 1, 2017. At the conclusion of this inaugural meeting, we met with the leaders of this exciting new consortium, who spoke candidly about the meeting, schwannomatosis research, and what is at stake for this important project. To enable closed captioning on each of the videos below, click the CC button.
Rick Horvitz, CTF Board of Directors Chair and project benefactor, answers the question, “What were your expectations going into this meeting?”
Ken Aldape, MD, of the University of Toronto, answers the question, “How will the work of this consortium accelerate the path to treatments?”
Gelareh Zadeh, MD, PhD, of the University of Toronto, and one of the co-Principal Investigators of the project, answers the question, “Can you discuss the aspect of the work that you are specifically working on?”
Gareth Evans, MD, of the University of Manchester answers the question, “What is the value of working in this consortium?”
Laura Papi, MD, PhD, of the University of Florence, Italy, and one of the co-Principal Investigators of the project, answers the question, “How is working in a consortium better or different than working in a traditional research model?”
Rick Horvitz, CTF Board of Directors Chair and project benefactor, answers the question, “What will all this mean for the NF patient?”
Synodos for Schwannomatosis is funded by the Children’s Tumor Foundation and will run for two years with a budget of $1.0 million. To read more about the inaugural meeting of this consortium, click here.
